You are here: Industry Insights > USPTO

News List

US grants new patent targeting major neurodegenerative diseases europeanpharmaceuticalreview
July 05, 2021
Alterity Therapeutics have been granted a patent for compounds able to redistribute excess iron in the brain being developed as a treatment for neurodegenerative diseases including Alzheimer’s and Parkinson’s.
USPTO grants patent to Tiziana for fully human monoclonal antibody, TZLS-501 expresspharma
August 25, 2020
The grant of this additional patent on TZLS-501 is of significance for the potential treatment of COVID-19 and other pulmonary diseases.
KemPharm Receives of Two Additional U.S. Patents americanpharmaceuticalreview
August 04, 2020
KemPharm announced the United States Patent and Trademark Office (USPTO) has recently issued two new patents to KemPharm governing methods of use and composition of matter for methylphenidate-based prodrugs.
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the USPTO americanpharmaceuticalreview
December 11, 2019
Biohaven Pharmaceutical announced the U.S. Patent and Trademark Office (USPTO) issued U.S. Pat. No. 10,485,791 on November 26, 2019 relating to troriluzole.
Forge Receives Notice of Allowance from USPTO Covering Novel Chemistry Targeting LpxC americanpharmaceuticalreview
August 15, 2019
Forge Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inhibitors of LpxC for the tr
USPTO Issues Patent for COM701, Anti-PD-1 Antibody Use americanpharmaceuticalreview
July 17, 2019
Compugen announced the United States Patent and Trademark Office (USPTO) has granted a new patent covering method of use of COM701, a first-in-class therapeutic antibody targeting PVRIG, in combination with anti-PD-1 antibodies.
USPTO Allows Patent Claims for CBM BioPharma Application for Pancreatic Cancer Treatment americanpharmaceuticalreview
June 27, 2019
CBM BioPharma announced the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance and Issue Fee Due in CBM's patent application related to the treatment of pancreatic cancer.
Amorsa Therapeutics Announces U.S. Patent Covering Deuterated Norketamine, Related Compounds americanpharmaceuticalreview
February 18, 2019
Amorsa Therapeutics announced its patent application for deuterated norketamine and related NMDA receptor modulators was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).....
AOBiome Expands Receives Patent for Use of AOB for Eczema Treatment americanpharmaceuticalreview
January 03, 2019
AOBiome Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company's Ammonia Oxidizing Bacteria (AOB) for the treatment eczema....
Compugen Announces Issuance of Patent for COM902 americanpharmaceuticalreview
November 14, 2018
Compugen Announces Issuance of Patent for COM902

Previous page 1 2 Next page